Diligence memo · auto-generated · as of July 2, 2026
Zumatek, Inc.
Zumatek, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Zumatek, Inc. operates in Biotechnology, based in CHAPEL HILL.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Zumatek, Inc. has raised $250K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $150K on 2010-09-02.
Most recent recorded round closed around 2010-09-02.
Valuation (modeled)modeled
Provath models Zumatek, Inc. at approximately $8.3M (range $80K–$94M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.42× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 15.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 6% of Biotechnology peers (4293 compared).
Modeled value ranks above 16% of those peers.
Closest niche peers: Hygeia Therapeutics, Inc., Act Biotech Inc, Ikonopedia, LLC, Iquum Inc, Koronis Pharma, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.